BBV152

Daripada Wikipedia, ensiklopedia bebas.
Jump to navigation Jump to search
BBV152
Butiran vaksin
Penyakit sasaranSARS-CoV-2
JenisTerinaktivasi
Terapi gen
Data klinikal
Nama dagangCovaxin
Kaedah
pemberian
Intraotot
Kod ATC
Data fisiologi
Status perundangan
Status perundangan
  • EUA : IND, IRN, ZBW, MU
Data farmakokinetik
Pengecam
DrugBank
Data kimia dan fizikal
Halaman data

BBV152 (juga disebut sebagai Covaxin) ialah vaksin COVID-19 yang mengandungi bahan berdasarkan virus tidak aktif. Vaksin tersebut dibangunkan oleh Bharat Biotech dengan kerjasama Badan Penyelidikan Perubatan India.[1][2][3][4][5][6]

Rujukan[sunting | sunting sumber]

  1. ^ "ICMR teams up with Bharat Biotech to develop Covid-19 vaccine". Livemint (dalam bahasa Inggeris). 9 May 2020.
  2. ^ Chakrabarti A (10 May 2020). "India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech". ThePrint.
  3. ^ "India's First COVID-19 Vaccine Candidate Approved for Human Trials". The New York Times. 29 June 2020.
  4. ^ "Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS". DD News. Prasar Bharati, Ministry of I & B, Government of India. 25 July 2020.
  5. ^ Press, Associated (25 July 2020). "Asia Today: Amid new surge, India tests potential vaccine". Washington Post. Dicapai pada 17 December 2020.
  6. ^ "Delhi: 30-year-old is first to get dose of trial drug Covaxin". The Indian Express (dalam bahasa Inggeris). 25 July 2020.

Pautan luar[sunting | sunting sumber]